In contrast, patients who despite their therapy still experienced hospitalized exacerbations, had a higher risk of stroke associated with anti-IgE therapy and a higher risk of PAD associated with anti-IgE or anti-IL5 therapy. This evidence concerns the gene IGHE and Stroke.